First described in 1888 by Romanian pathologist Victor Babes — after whom the genus was named — Babesia parasites are found worldwide. Over 100 distinct species exist, of which several are known to infect humans. What makes Babesia particularly significant in the context of tick-borne illness is not just what it does on its own, but how dramatically it can worsen Lyme disease when the two infections occur together in the same patient.
The most important thing to understand about Babesia
Babesia is a parasite, not a bacterium. This is not a technicality — it has direct clinical consequences. Standard Lyme disease antibiotics (doxycycline, amoxicillin, cefuroxime) have no meaningful effect on Babesia. A patient being treated for Lyme disease while also carrying an unrecognised Babesia co-infection will not improve as expected — and may continue to deteriorate — until the Babesia is specifically identified and treated with antiparasitic drugs.
A blood parasite that destroys red blood cells
Babesia parasites belong to the same biological phylum as the organisms that cause malaria (Plasmodium), toxoplasmosis, and cryptosporidiosis. Like malaria parasites, Babesia enters the bloodstream and invades red blood cells, where it reproduces by budding. As infected cells rupture, they release new parasites that infect further cells — causing cycles of red blood cell destruction and the release of cellular debris into the bloodstream. This process is called haemolytic anaemia, and it is the central mechanism behind Babesia's symptoms.
The Maltese cross — a diagnostic signature
When Babesia reproduces inside a red blood cell, four daughter cells often remain attached at their centre, forming a characteristic cross or X shape — called the tetrad or "Maltese cross" form. This is pathognomonic for Babesia: no other known parasite forms this structure inside human red blood cells. On a blood smear examined under microscopy, the Maltese cross confirms Babesia infection.
However — and this is important — the Maltese cross is not always visible. Parasitemia (the percentage of infected red blood cells) is often very low, particularly in early or chronic infection. Low parasitemia means the infected cells can be missed on a smear, even by an experienced technician. PCR testing is more sensitive for low-level infection.
Three species are clinically significant in humans:
The most common cause of human babesiosis worldwide. Transmitted by Ixodes scapularis in the northeastern and upper midwestern United States — the same tick that carries Lyme disease. Also found in Europe. Causes illness ranging from asymptomatic to severe. Approximately one third of infected people remain completely asymptomatic.
Found on the US West Coast — California, Washington, Oregon. Generally considered more virulent than B. microti, causing more severe illness even in otherwise healthy individuals. Standard serological tests for B. microti may not cross-react with B. duncani, making it easy to miss if only tested with microti antigen.
The primary Babesia species in Europe, transmitted by Ixodes ricinus — the same tick that carries Lyme in Europe. Historically caused severe and often fatal disease, predominantly in asplenic (spleen-removed) patients. B. venatorum (formerly EU1), related to deer parasites, also causes cases in Europe and Asia.
How Babesia reaches humans
The primary transmission route is a bite from an infected Ixodes tick. The life cycle mirrors that of Lyme disease: the tick acquires Babesia from small rodents (particularly the white-footed mouse) during larval feeding, carries it into adulthood, and transmits it during its next blood meal. Because B. microti and B. burgdorferi share the same tick vector in the northeastern US and Europe, co-infection from a single tick bite is not uncommon — one tick can transmit both simultaneously.
Unlike Lyme disease, Babesia can be transmitted through blood transfusion. Because many infected people are asymptomatic, they may donate blood without knowing they carry the parasite. Babesia microti has become one of the most common parasites transmitted through blood transfusion in the United States. This is a genuine public health problem that mainstream medicine has been slow to address — blood supply screening for Babesia only became available in parts of the US in 2019, and coverage remains incomplete. For people with compromised immune systems who receive blood products, this risk is real and not theoretical.
Babesia can be transmitted from mother to child during pregnancy. Neonatal babesiosis is rare but documented, and can be severe in newborns. This transmission route is rarely discussed and poorly recognised even by specialists.
What Babesia feels like
Babesia produces a malaria-like illness — not in terms of geographic origin, but in terms of mechanism and presentation. Both malaria and babesiosis are caused by parasites that invade and destroy red blood cells in cycles, producing waves of fever, chills, and sweating as infected cells burst and the body responds with an acute immune reaction.
A key feature: approximately one third of people infected with B. microti remain entirely asymptomatic, particularly younger healthy adults. The severity of illness correlates strongly with immune status — those most at risk for severe babesiosis are the elderly, those without a spleen, and those with underlying immune compromise.
- High fever — often cyclic, coming in waves
- Drenching chills and rigors
- Profuse sweating as fever breaks
- Severe headache
- Nausea and loss of appetite
- Myalgia — deep muscle aching
- Arthralgia — joint pain
- Extreme fatigue and weakness
- Pallor — pale skin, pale lips
- Jaundice — yellow tinge to skin or eyes
- Dark urine (tea- or cola-coloured)
- Shortness of breath on exertion
- Rapid heart rate
- Enlarged spleen (splenomegaly)
- Enlarged liver (hepatomegaly)
- Air hunger — sensation of not getting enough air, even at rest
- Night sweats — often the most distinctive feature
- Emotional lability — mood swings, irritability
- Cognitive fog, difficulty concentrating
- Dizziness or light-headedness
- Chest discomfort or pressure
- Very high parasitemia (up to 85% of RBCs in asplenic)
- Haemodynamic instability — low blood pressure
- Acute respiratory distress syndrome
- Renal failure
- Disseminated intravascular coagulation
- Organ failure — potentially fatal without intervention
Among all Babesia symptoms, "air hunger" — a persistent sensation of not getting enough breath, sometimes described as needing to sigh repeatedly or feeling unable to fill the lungs — is considered one of the most clinically distinctive. It is not typical of Lyme disease alone, and its presence in a Lyme patient should prompt specific investigation for Babesia. Night sweats — not just mild perspiration but truly drenching sweats that soak bedclothes — are similarly characteristic and often the first symptom that persists even when other symptoms seem to improve.
Severity depends heavily on immune status
Babesia has a wide spectrum of disease severity — from asymptomatic to life-threatening — and this spectrum correlates closely with the patient's immune status and spleen function. Understanding who is at highest risk is important for triaging who needs aggressive diagnosis and treatment.
The spleen plays a critical role in filtering Babesia-infected red blood cells from circulation. People who have had their spleen removed (splenectomy) — often after trauma or haematological disease — can develop fulminant, rapidly fatal babesiosis. Parasitemia can reach 85% of all red blood cells. Anyone without a spleen who lives in an endemic area should be aware that any febrile illness after a tick bite may be Babesia.
Age brings reduced immune responsiveness and often some degree of spleen dysfunction. Elderly patients with Babesia are at substantially higher risk of severe disease, prolonged illness, and death compared to younger healthy adults. The infection may initially be dismissed as an ordinary flu — with life-threatening consequences.
HIV/AIDS, active cancer, organ transplant patients, and those on long-term immunosuppressive medications are at risk of severe and relapsing babesiosis. These patients may require extended treatment (6 weeks or more rather than 7–10 days) and careful monitoring for relapse. The threshold for initiating treatment should be lower in this group.
Even in people with normal immune function, Babesia co-infection significantly worsens the clinical course of Lyme disease. Patients co-infected with both Lyme and Babesia experience more severe symptoms, longer illness, and poorer treatment response than those with Lyme alone. Crucially, standard Lyme treatment does nothing against the Babesia component.
Approximately one third of healthy, immunocompetent adults infected with B. microti remain completely asymptomatic. Their infection may be detected incidentally (e.g. during blood donation screening) or go entirely undetected. However, asymptomatic carriers can still transmit Babesia through blood donation — and may develop symptoms if their immune status later changes.
How to confirm a Babesia infection
Unlike Bartonella, Babesia is relatively straightforward to confirm in acute symptomatic infection — but low-level or chronic infection can still be missed by standard tests. Several approaches are available, and they complement each other.
The classic diagnostic test. A thin blood smear is examined under microscopy for intra-erythrocytic parasites. The Maltese cross tetrad form, if visible, is pathognomonic. However, sensitivity depends heavily on the level of parasitemia — low-level infection (less than 1% of cells infected) can easily be missed. A negative smear does not rule out Babesia in symptomatic patients.
More sensitive than blood smear for detecting low parasitemia. PCR detects Babesia DNA directly. Important note: B. microti PCR will not detect B. duncani, and vice versa — species-specific testing matters. In western US exposure, testing for both B. microti and B. duncani is recommended. Specialist labs (IGeneX, Galaxy Diagnostics) offer more comprehensive species coverage.
Antibody tests detect the immune response to Babesia. Useful for confirming past or chronic infection. Important caveat: Babesia antibodies can persist for a year or more after apparent clearance, so a positive antibody test alone does not confirm active infection. Antibodies to B. microti do not cross-react with B. duncani — tests must include both antigens for patients exposed on the west coast.
IGeneX and Galaxy Diagnostics offer more sensitive Babesia testing panels that cover multiple species — including B. duncani, B. divergens, and B. odocoilei — that standard hospital laboratories do not test for. For patients with Lyme co-infection, or those in whom standard testing is negative despite strong clinical suspicion, specialist testing is the appropriate next step.
Antiparasitic treatment — not antibiotics
Because Babesia is a parasite, not a bacterium, it requires antiparasitic drugs — not the antibiotics used for Lyme disease. This is the single most important practical consequence of understanding what Babesia actually is. A patient on doxycycline for Lyme who also has Babesia will not improve the Babesia component at all.
The preferred combination for non-life-threatening babesiosis. Atovaquone (750 mg twice daily) is an antiparasitic agent that disrupts the parasite's mitochondrial function. Azithromycin (500 mg on day 1, then 250 mg daily) is added for its synergistic antiparasitic effect. Standard course: 7–10 days for immunocompetent patients.
Side effects are generally mild — mainly diarrhoea and rash. The combination is well-tolerated compared to older regimens. In immunocompromised patients, treatment may need to extend to 6 weeks or longer, and higher azithromycin doses are often used.
The older standard regimen, now considered an alternative due to its significant side effect profile. Quinine frequently causes tinnitus, hearing loss, dizziness, and gastrointestinal distress — up to 72% of patients experience adverse effects, and many require treatment discontinuation.
Still sometimes used for severe cases or treatment-resistant infection. Exchange transfusion — removing a large proportion of infected red blood cells and replacing with donor blood — is reserved for very severe cases with high parasitemia and is potentially lifesaving.
Babesial parasitemia is notably resistant to clearance — it can persist for weeks even with appropriate treatment. Delayed clearance is considered normal. However, patients who are immunocompromised, asplenic, or co-infected with other tick-borne illnesses may experience relapse after completing treatment, and sometimes require repeated or prolonged courses. If Lyme treatment has been ongoing without adequate response, consideration of untreated Babesia co-infection should always be on the differential.
Babesia and Lyme together — why it matters so much
The co-occurrence of Babesia and Lyme disease is not an unusual edge case — it is common enough that any Lyme patient in an endemic area who is not responding adequately to treatment should be specifically evaluated for Babesia. The presence of both infections simultaneously worsens outcomes in documented ways.
Research shows that Lyme patients co-infected with Babesia have more symptoms, more severe symptoms, and longer illness duration than those with Lyme alone. The immune system is simultaneously dealing with a bacterial infection and an active parasitic infection destroying red blood cells — the combined burden is greater than either alone.
Standard Lyme treatment protocols were designed for Lyme disease alone. They do not include atovaquone or any antiparasitic agent. A patient receiving textbook Lyme treatment who also has Babesia is receiving zero treatment for 50% of their infection. This is one of the most clinically significant reasons why some Lyme patients plateau or deteriorate despite apparently adequate antibiotic treatment.
The characteristic clues that Babesia may be present alongside Lyme: air hunger, drenching night sweats, cyclic high fevers with chills and sweating, unusual fatigue pattern, pale skin or jaundice, and failure to improve despite appropriate Lyme treatment. Any of these in a Lyme patient should prompt specific Babesia investigation.
Sources & further reading
- Columbia University Lyme and Tick-Borne Disease Research Center — Babesiosis overview
- Krause PJ et al. — Atovaquone and Azithromycin for the Treatment of Babesiosis. NEJM, 2000
- IDSA 2020 Guideline on Diagnosis and Management of Babesiosis
- Cameron D — Babesia and Lyme: It's Worse Than You Think, danielcameronmd.com
- Human Babesiosis: Pathogens, Prevalence, Diagnosis and Treatment — PMC4649939
- IGeneX — Babesia testing panels, igenex.com
- New York State DOH — Babesiosis Fact Sheet
Last updated: April 2026